Turnstone Biologics Corp.

NasdaqGM:TSBX Stock Report

Market Cap: US$13.0m

Turnstone Biologics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Sammy Farah

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage47.3%
CEO tenure9.3yrs
CEO ownershipn/a
Management average tenureless than a year
Board average tenure6yrs

Recent management updates

Recent updates

We're A Little Worried About Turnstone Biologics' (NASDAQ:TSBX) Cash Burn Rate

May 08
We're A Little Worried About Turnstone Biologics' (NASDAQ:TSBX) Cash Burn Rate

Here's Why We're A Bit Worried About Turnstone Biologics' (NASDAQ:TSBX) Cash Burn Situation

Jan 23
Here's Why We're A Bit Worried About Turnstone Biologics' (NASDAQ:TSBX) Cash Burn Situation

CEO Compensation Analysis

How has Sammy Farah's remuneration changed compared to Turnstone Biologics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$74m

Jun 30 2024n/an/a

-US$75m

Mar 31 2024n/an/a

-US$75m

Dec 31 2023US$1mUS$532k

-US$55m

Sep 30 2023n/an/a

-US$52m

Jun 30 2023n/an/a

-US$51m

Mar 31 2023n/an/a

-US$29m

Dec 31 2022US$3mUS$501k

-US$31m

Compensation vs Market: Sammy's total compensation ($USD1.12M) is above average for companies of similar size in the US market ($USD641.95K).

Compensation vs Earnings: Sammy's compensation has been consistent with company performance over the past year.

CEO

Sammy Farah (52 yo)

9.3yrs

Tenure

US$1,123,756

Compensation

Dr. Sammy J. Farah, MBA, Ph D., serves as President, Chief Executive Officer & Director at Turnstone Biologics Corp. since October 2015. He serves as President and Chief Executive Officer at Turnstone Biol...

Leadership Team

NamePositionTenureCompensationOwnership
Sammy Farah
President9.3yrsUS$1.12mno data
Michael Burgess
Executive Director3.6yrsno data0%
$ 0
Wendy Worcester
VP, Principal Finance & Accounting Officerless than a yearno datano data
Saryah Azmat
Chief Operating Officerless than a yearUS$1.06m0%
$ 0
David Stojdl
Senior Vice President of Research & Discoveryno datano datano data
Ines Verdon
Senior Vice President of Clinical Developmentless than a yearno datano data
Michael Fitch
Senior Vice President of Manufacturingless than a yearno datano data

0.6yrs

Average Tenure

52yo

Average Age

Experienced Management: TSBX's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Sammy Farah
President9.3yrsUS$1.12mno data
Michael Burgess
Executive Director3.6yrsno data0%
$ 0
William Waddill
Independent Directorless than a yearno datano data
Malcolm Brenner
Member of Scientific Advisory Boardno datano datano data
Bernard Fox
Member of the Scientific Advisory Boardno datano datano data
Rishi Gupta
Independent Director8.3yrsUS$77.73k0%
$ 0
Robert Gould
Independent Director6yrsUS$23.01k0%
$ 0
James Mule
Member of the Scientific Advisory Boardno datano datano data
Jerel Davis
Independent Chairman of the Board & Lead Independent Director9.3yrsUS$88.68k0%
$ 0
Kanya Rajangam
Independent Director3.2yrsUS$57.78k0%
$ 0
Adrian Hill
Member of the Scientific Advisory Boardno datano datano data
Alan Melcher
Member of the Scientific Advisory Boardno datano datano data

6.0yrs

Average Tenure

64yo

Average Age

Experienced Board: TSBX's board of directors are considered experienced (6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 00:07
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Turnstone Biologics Corp. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBofA Global Research
Charlie YangBofA Global Research
Daina GrayboschLeerink Partners LLC